Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia

NCT00792831 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
3
Enrollment
INDUSTRY
Sponsor class

Stopped Protocol needs complete restructuring in order to make it feasible and to complete the enrollment of 23 patients.

Conditions

Interventions

Sponsor

Italfarmaco